Quarterly Report • Nov 6, 2018
Quarterly Report
Open in ViewerOpens in native device viewer
3RD QUARTER 2018 | 1ST NINE MONTHS 2018
| 3rd quarter | 1st nine months | ||||
|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | |
| Sales | 3,794 | 3,556 | 11,343 | 10,810 | |
| Adjusted EBITDAa | 692 | 640 | 2,114 | 1,874 | |
| Adjusted EBITDA margin in % | 18.2 | 18.0 | 18.6 | 17.3 | |
| Adjusted EBITb | 468 | 423 | 1,462 | 1,245 | |
| Income before financial result and income taxes, continuing operations (EBIT) | 449 | 392 | 1,399 | 1,047 | |
| Net income | 329 | 227 | 928 | 606 | |
| Adjusted net income | 370 | 275 | 1,057 | 816 | |
| Earnings per share in € | 0.71 | 0.49 | 1.99 | 1.30 | |
| Adjusted earnings per share in € | 0.79 | 0.59 | 2.27 | 1.75 | |
| Cash flow from operating activities | 542 | 727 | 1,146 | 1,033 | |
| Cash outflows for investments in intangible assets, property, plant and equipment | –240 | –242 | –704 | –683 | |
| Free cash flowc | 302 | 485 | 442 | 350 | |
| Net financial debt as on the balance sheet as of September 30 | – | – | –3,188 | –3,156 | |
| No. of employees as of September 30 | – | – | 36,316 | 36,573 |
Prior-year figures restated.
a Earnings before financial result, taxes, depreciation and amortization, after adjustments.
b Earnings before financial result and taxes, after adjustments.
c Cash flow from operating activities less cash outflows for investment in intangible assets, property, plant and equipment.
Due to rounding, some figures in this report may not add up exactly to the totals stated.
| Business conditions and performance | 4 |
|---|---|
| Business performance | 4 |
| Segment performance | 7 |
| Financial condition | 11 |
| Expected development | 12 |
| Income statement | 13 |
| Balance sheet | 14 |
| Cash flow statement | 15 |
| Segment report | 16 |
| Appendix—Restatement of prior-year figures | 20 |
| Financial calendar | 23 |
| Credits | 23 |
a By location of customer.
Evonik once again posted a successful business performance. With demand remaining good and higher selling prices, both sales and adjusted EBITDA increased. The Nutrition & Care and Resource Efficiency growth segments generated considerably higher earnings. Group-wide, the first visible success of the program to reduce selling and administrative expenses contributed to the improvement in earnings.
2018 2017
Prior-year figures restated.
The Evonik Group grew sales 7 percent to €3,794 million. The 8 percent organic sales growth was driven by higher selling prices, resulting in some cases from passing on higher raw material costs. Volumes declined slightly, partly due to the restrictions on the transportation of goods due to the low water levels of the river Rhine. One percentage point came from the initial consolidation of the silica business acquired from J.M. Huber Corporation, Atlanta (Georgia, USA), effective September 1, 2017. Negative exchange rate movements had a countereffect.
| in % | 1st quarter 2018 |
2nd quarter 2018 |
3rd quarter 2018 |
1st nine months 2018 |
|---|---|---|---|---|
| Volumes | 1 | 3 | –1 | 1 |
| Prices | 4 | 4 | 9 | 6 |
| Organic sales growth | 5 | 7 | 8 | 7 |
| Exchange rates | –5 | –3 | –1 | –3 |
| Change in the scope of consolidation/ other effects |
1 | 3 | – | 1 |
| Total | 1 | 7 | 7 | 5 |
2018 2017 Prior-year figures restated.
Adjusted EBITDA rose 8 percent to €692 million. The adjusted EBITDA margin increased from 18.0 percent in the prior-year quarter to 18.2 percent.
The adjustments of – €19 million contain restructuring expenses of €4 million in connection with the reduction in selling and administrative expenses. Also included are project expenses of a further €3 million for the integration of the businesses acquired in 2017. Other includes expenses for examining the options for the future development of the methacrylates business. The prior-year adjustments principally comprised costs in connection with the acquisition of the silica business from Huber and the specialty additives business from Air Products and Chemicals, Inc., Allentown (Pennsylvania, USA). The financial result improved to –€42 million. The prior-year figure of –€62 million contained special items totaling –€7 million, mainly for currency hedging in connection with the acquisition of the Huber silica business. The adjusted financial result improved by €14 million to –€41 million. Income before income taxes, continuing operations rose 23 percent to €407 million. The income tax rate and adjusted income tax rate were both 19 percent, partly due to non-period tax income.
Overall, net income improved 45 percent to €329 million.
The calculation of adjusted net income (after adjustment for special items) improves comparability of the earnings power of the continuing operations, especially on a long-term view, and thus facilitates the forecasting of future development. In the third quarter of 2018 it rose 35 percent to €370 million. Adjusted earnings per share increased from €0.59 to €0.79.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % | |
| Sales | 3,794 | 3,556 | 7 | 11,343 | 10,810 | 5 | |
| Adjusted EBITDA | 692 | 640 | 8 | 2,114 | 1,874 | 13 | |
| Adjusted depreciation, amortization and impairment losses | –224 | –217 | –652 | –629 | |||
| Adjusted EBIT | 468 | 423 | 11 | 1,462 | 1,245 | 17 | |
| Adjustments | –19 | –31 | –63 | –198 | |||
| thereof attributable to | |||||||
| Restructuring | –4 | –6 | –26 | –19 | |||
| Impairment losses/reversals of impairment losses | – | 1 | 7 | 2 | |||
| Acquisition/divestment of shareholdings | –3 | –19 | –14 | –145 | |||
| Other | –12 | –7 | –30 | –36 | |||
| Financial result | –42 | –62 | –141 | –153 | |||
| Income before income taxes, continuing operations | 407 | 330 | 23 | 1,258 | 894 | 41 | |
| Income taxes | –76 | –101 | –319 | –278 | |||
| Income after taxes, continuing operations | 331 | 229 | 45 | 939 | 616 | 52 | |
| Income after taxes, discontinued operations | 3 | 2 | 4 | 4 | |||
| Income after taxes | 334 | 231 | 45 | 943 | 620 | 52 | |
| thereof attributable to non-controlling interests | 5 | 4 | 15 | 14 | |||
| Net income | 329 | 227 | 45 | 928 | 606 | 53 | |
| Earnings per share in € | 0.71 | 0.49 | – | 1.99 | 1.30 | – |
Prior-year figures restated.
| 3rd quarter | 1st nine months | |||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % |
| Adjusted EBITDA | 692 | 640 | 8 | 2,114 | 1,874 | 13 |
| Adjusted depreciation, amortization and impairment losses | –224 | –217 | –652 | –629 | ||
| Adjusted EBIT | 468 | 423 | 11 | 1,462 | 1,245 | 17 |
| Adjusted financial result | –41 | –55 | –138 | –140 | ||
| Amortization and impairment losses on intangible assets | 34 | 34 | 109 | 98 | ||
| Adjusted income before income taxes a | 461 | 402 | 15 | 1,433 | 1,203 | 19 |
| Adjusted income taxes | –86 | –123 | –361 | –373 | ||
| Adjusted income after taxes a | 375 | 279 | 34 | 1,072 | 830 | 29 |
| thereof adjusted income attributable to non-controlling interests |
5 | 4 | 15 | 14 | ||
| Adjusted net incomea | 370 | 275 | 35 | 1,057 | 816 | 30 |
| Adjusted earnings per sharea in € | 0.79 | 0.59 | – | 2.27 | 1.75 | – |
Prior-year figures restated.
a Continuing operations.
Sales grew 5 percent to €11,343 million. We posted organic sales growth of 7 percent, driven by a slight rise in volumes (1 percentage point) and higher selling prices (6 percentage points). Initial consolidation of the silica business acquired from Huber with effect from September 1, 2017 contributed 1 percentage point. Sales growth was held back by negative currency effects (– 3 percentage points).
Adjusted EBITDA rose 13 percent to €2,114 million. The adjusted EBITDA margin rose from 17.3 percent in the first nine months of 2017 to 18.6 percent.
The adjustments of –€63 million include –€26 million relating to restructuring, primarily for the shutdown of a production site in Hungary. The adjustments also contain –€14 million relating to the purchase/disposal of investments, principally in connection with integration of the businesses acquired in 2017. In addition, other includes expenses for examining the options for the future development of the methacrylates business. The prior-year figure of –€198 million mainly comprised expenses in connection with the acquisitions made in 2017. The financial result improved to – €141 million. The prior-year figure of – €153 million included interest income of €17 million from tax refunds and special items of –€13 million, mainly for currency hedging of the acquisition of the Huber silica business. After adjustment for special items, the financial result improved by €2 million to –€138 million. Income before income taxes, continuing operations increased 41 percent to €1,258 million. The income tax rate and adjusted income tax rate were both 25 percent, partly as a consequence of non-period tax income.
Net income rose 53 percent to €928 million.
After special items, adjusted net income increased 30 percent to €1,057 million, while adjusted earnings per share rose from €1.75 to €2.27.
As part of its concentration on specialty chemicals, Evonik is focusing on its four defined growth engines, Specialty Additives, Animal Nutrition, Smart Materials, and Health & Care, which are characterized by above-average growth and low cyclical exposure. In 2018, we initiated major steps in the ongoing development of our portfolio:
On March 6, 2018, the Executive Board of Evonik Industries AG decided to examine all options for the future development of the methacrylates business. These options include potential partnerships and complete separation. The methacrylates business does not form part of the defined growth engines; it comprises large-volume monomers such as methylmethacrylate (MMA), various specialty monomers, and the PLEXIGLAS brand of PMMA molding compounds and semi-finished products.
At the end of August 2018, Evonik signed an agreement to divest its Jayhawk site in Galena (Kansas, USA). This site is operated by the Performance Materials Segment and produces precursors for agrochemicals, which are not included in the growth businesses defined by Evonik. On the balance sheet, these activities have been reclassified as held for sale.
To strengthen our Health & Care growth engine, at the start of 2019 we will be merging our personal care and household products businesses, together with the associated oleochemical technology platform. The new Care Solutions unit will concentrate on clearly differentiated specialties. This new structure should make processes more efficient and leverage synergies. In addition, two sites in the UK and Spain are to be closed.
Good progress is being made with the program introduced in fall 2017 to bring a lasting reduction of €200 million in selling and administrative expenses. The first €50 million savings will be achieved this year. Initial measures to realize the remaining €150 million are now being implemented.
| 3rd quarter | 1st nine months | |||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % |
| External sales | 1,167 | 1,110 | 5 | 3,474 | 3,393 | 2 |
| Adjusted EBITDA | 212 | 188 | 13 | 643 | 575 | 12 |
| Adjusted EBITDA margin in % | 18.2 | 16.9 | – | 18.5 | 16.9 | – |
| Adjusted EBIT | 141 | 116 | 22 | 438 | 374 | 17 |
| Capital expendituresa | 94 | 91 | 3 | 341 | 246 | 39 |
| No. of employees as of September 30 | – | – | – | 8,237 | 8,330 | –1 |
Prior-year figures restated.
a Capital expenditures for intangible assets, property, plant and equipment.
The Nutrition & Care Segment grew sales 5 percent to €1,167 million in the third quarter of 2018. This was due to significantly higher volumes and selling prices, while exchange rates had a negative effect.
Market conditions for essential amino acids for animal nutrition, especially methionine, remained robust. Sales volumes developed positively and were significantly higher than in the prior-year quarter. Measures to reduce costs were implemented successfully. The health care business performed very well and generated a substantial rise in sales. The business with specialties for industrial markets also registered higher sales as a result of increased demand. A better product mix led to a rise in sales of personal care products.
2018 2017
Prior-year figures restated.
Adjusted EBITDA increased 13 percent to €212 million, thanks to volume growth, the systematic focus on higher-margin products, and successful cost savings. The adjusted EBITDA margin improved significantly from 16.9 percent in the prioryear quarter to 18.2 percent.
Prior-year figures restated.
In the first nine months of 2018, the Nutrition & Care Segment's sales rose 2 percent to €3,474 million. This was attributable to higher volumes and selling prices. The increase was held back by negative currency effects. Adjusted EBITDA advanced 12 percent to €643 million and the adjusted EBITDA margin improved significantly to 18.5 percent.
| 3rd quarter | 1st nine months | |||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % |
| External sales | 1,426 | 1,358 | 5 | 4,305 | 4,085 | 5 |
| Adjusted EBITDA | 338 | 311 | 9 | 1,029 | 926 | 11 |
| Adjusted EBITDA margin in % | 23.7 | 22.9 | – | 23.9 | 22.7 | – |
| Adjusted EBIT | 264 | 242 | 9 | 805 | 720 | 12 |
| Capital expendituresa | 60 | 79 | –24 | 174 | 214 | –19 |
| No. of employees as of September 30 | – | – | – | 10,318 | 10,284 | – |
Prior-year figures restated.
a Capital expenditures for intangible assets, property, plant and equipment.
The Resource Efficiency Segment continued to develop successfully in the third quarter of 2018. Sales rose 5 percent to €1,426 million, driven mainly by higher selling prices, partly because higher raw material costs were passed on to customers, and by the consolidation of the Huber silica business, which was acquired on September 1, 2017. The rise was reduced by slightly lower volumes and negative currency effects.
Sales of high-performance polymers increased significantly. Since there was strong demand for products for lightweight structures, higher prices had a positive effect. Coating additives benefited from high demand for water-based, environmentfriendly paints and coatings and also generated significantly higher sales. Consolidation of the acquired silica business increased sales of silica.
2018 2017 Prior-year figures restated. Adjusted EBITDA rose 9 percent to €338 million, mainly on price grounds. The adjusted EBITDA margin rose from 22.9 percent to 23.7 percent.
2018 2017
Prior-year figures restated.
In the first nine months of 2018, sales in the Resource Efficiency Segment rose 5 percent to €4,305 million. Alongside first-time consolidation of the Huber silica business, which was acquired on September 1, 2017, this was attributable to higher selling prices. Negative currency movements had a countereffect. Adjusted EBITDA increased 11 percent to €1,029 million. The adjusted EBITDA margin improved from 22.7 percent in the prior-year period to 23.9 percent.
| 3rd quarter | 1st nine months | |||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % |
| External sales | 1,034 | 913 | 13 | 3,054 | 2,781 | 10 |
| Adjusted EBITDA | 172 | 172 | – | 546 | 497 | 10 |
| Adjusted EBITDA margin in % | 16.6 | 18.8 | – | 17.9 | 17.9 | – |
| Adjusted EBIT | 138 | 133 | 4 | 445 | 386 | 15 |
| Capital expendituresa | 27 | 35 | –23 | 75 | 103 | –27 |
| No. of employees as of September 30 | – | – | – | 4,264 | 4,458 | –4 |
Prior-year figures restated.
a Capital expenditures for intangible assets, property, plant and equipment.
The Performance Materials Segment grew sales 13 percent to €1,034 million in the third quarter of 2018. This was attributable to a significant rise in selling prices, mainly because higher raw material costs were passed on to customers, but was held back by negative currency effects. Volumes declined as a result of restrictions on the transportation of goods due to the low water levels in the river Rhine.
Methacrylates again performed very well and generated higher sales. High demand, especially from the coatings and automotive sectors, coincided with sustained tight supply on the market. Sales of performance intermediates increased significantly thanks to the raw material-driven rise in selling prices.
2018 2017
Prior-year figures restated.
Adjusted EBITDA was unchanged from the prior year at €172 million. The adjusted EBITDA margin was 16.6 percent, down from 18.8 percent in the prior-year period.
Prior-year figures restated.
In the first nine months of 2018, sales in the Performance Materials Segment rose 10 percent to €3,054 million. While currency movements had a negative effect, growth came from higher selling prices. Adjusted EBITDA improved 10 percent to €546 million and the adjusted EBITDA margin was 17.9 percent.
| 3rd quarter | 1st nine months | |||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | Change in % | 2018 | 2017 | Change in % |
| External sales | 164 | 172 | –5 | 499 | 539 | –7 |
| Adjusted EBITDA | 49 | 49 | – | 133 | 130 | 2 |
| Adjusted EBITDA margin in % | 29.9 | 28.5 | – | 26.7 | 24.1 | – |
| Adjusted EBIT | 10 | 18 | –44 | 31 | 37 | –16 |
| Capital expendituresa | 33 | 27 | 22 | 79 | 82 | –4 |
| No. of employees as of September 30 | – | – | – | 12,979 | 12,875 | 1 |
Prior-year figures restated.
a Capital expenditures for intangible assets, property, plant and equipment.
In the third quarter of 2018, sales declined 5 percent to €164 million, mainly as a result of lower revenues from procurement for external customers at our sites. Adjusted EBITDA was unchanged from the prior year at €49 million.
Sales dropped 7 percent to €499 million in the first nine months of 2018. Adjusted EBITDA increased 2 percent to €133 million, partly due to higher earnings contributions from Site Management.
Net financial debt increased to €3,188 million, which was €165 million more than on December 31, 2017. The slight rise was principally due to cash outflows that occur regularly in the second quarter, such as annual bonus payments and payment of the dividend for fiscal 2017 (€536 million). The cash flows from the operating business had a positive effect in the first nine months.
| in € million | Sep. 30, 2018 |
Dec. 31, 2017 |
|---|---|---|
| Non-current financial liabilitiesa | –3,681 | –3,694 |
| Current financial liabilitiesa | –248 | –351 |
| Financial debt | –3,929 | –4,045 |
| Cash and cash equivalents | 717 | 1,004 |
| Current securities | 8 | 9 |
| Other financial investments | 16 | 9 |
| Financial assets | 741 | 1,022 |
| Net financial debt as stated on the balance sheet |
–3,188 | –3,023 |
a Excluding derivatives and refund liabilities under rebate and bonus agreements.
In the first nine months of 2018, capital expenditures for property, plant and equipment were €678 million (9M 2017: €657 million). A production facility for precipitated silica for the tire industry came on stream in South Carolina (USA) and a new production line for specialty polyamide 12 powder (PA12) was taken into service in Marl (Germany). In principle, there is a slight timing difference in outflows for property, plant and equipment due to payment terms. In the reporting period, cash outflows for property, plant and equipment totaled €704 million (9M 2017: €683 million).
| 1st nine months | ||||
|---|---|---|---|---|
| in € million | 2018 | 2017 | ||
| Cash flow from operating activities | 1,146 | 1,033 | ||
| Cash outflows for investments in intangible assets, property, plant and equipment |
–704 | –683 | ||
| Free cash flow | 442 | 350 | ||
| Cash flow from other investing activities | –75 | –4,136 | ||
| Cash flow from financing activities | –650 | – | ||
| Change in cash and cash equivalents | –283 | –3,786 |
The cash flow from operating activities increased by €113 million to €1,146 million in the first nine months. This was mainly due to the improvement in operating earnings, while the rise was held back by a higher rise in net working capital. Due to the increase in the cash flow from operating activities, the free cash flow improved by €92 million to €442 million.
The cash flow from other investing activities comprised an outflow of €75 million. The high prior-year figure principally comprised outflows for the acquisition of the Air Products specialty additives business and the Huber silica business. The cash outflow of €650 million for financing activities was primarily for payment of the dividend for 2017 (€536 million).
We revised our forecast for global growth in our half year financial report due to the emerging economic slowdown caused by the US administration's protectionist measures and slower growth in some emerging markets. Our forecast for global economic conditions in 2018 has not changed since then. Overall, we anticipate a year-on-year growth rate of 3.2 percent in 2018.
The projection for the global economy is affected by mounting uncertainties. For example, we see a risk that escalation of the trade disputes could put a perceptible brake on global economic activity. Moreover, economic momentum could be dampened by a further increase in the already elevated political risks in the European Union, including the still unresolved issue of the UK's exit. Finally, there are initial signs that the goal of normalizing US monetary policy could unsettle the capital markets, leading to correction phases on the financial markets or a reversal of capital flows. This would adversely affect the emerging markets, in particular, and hold back the global economy.
Our forecast is based on the following assumptions:
We are reiterating the revised outlook for key figures published in August 2018:
| Forecast performance indicators | 2017 | Original forecast for 2018a |
Forecast for 2018 as revised in August 2018b |
|---|---|---|---|
| Group sales | €14.4 billion | Slight increase | Unchanged |
| Adjusted EBITDA | €2.357 billion | Between €2.4 billion and €2.6 billion |
Between €2.60 billion and €2.65 billion |
| ROCEc | 11.2 percent | Above the cost of capital, about level with the prior year |
Unchanged |
| Capital expendituresd | €1.1 billion | Around €1.0 billion | Unchanged |
| Free cash flow | €0.5 billion | Slightly above the prior year | Notably above the prior year |
Prior-year figures restated.
a See Financial Report 2017.
b See Half Year Financial Report 2018.
c Return on capital employed.
d Capital expenditures for intangible assets, property, plant and equipment.
1 Assumption at start of the year: 3.3 percent; adjusted to 3.2 percent in August 2018.
2 Assumption at start of the year: US\$1.20; adjusted to US\$1.26 in May 2018 and to US\$1.20 in August 2018.
| 3rd quarter | 1st nine months | ||||
|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | |
| Sales | 3,794 | 3,556 | 11,343 | 10,810 | |
| Cost of sales | –2,620 | –2,424 | –7,705 | –7,381 | |
| Gross profit on sales | 1,174 | 1,132 | 3,638 | 3,429 | |
| Selling expenses | –438 | –417 | –1,301 | –1,258 | |
| Research and development expenses | –111 | –116 | –331 | –345 | |
| General administrative expenses | –158 | –171 | –489 | –518 | |
| Other operating income | 45 | 55 | 147 | 170 | |
| Other operating expense | –64 | –93 | –270 | –438 | |
| Result from investments recognized at equity | 1 | 2 | 5 | 7 | |
| Income before financial result and income taxes, continuing operations |
449 | 392 | 1,399 | 1,047 | |
| Interest income | 7 | 8 | 16 | 41 | |
| Interest expense | –49 | –62 | –157 | –177 | |
| Other financial income/expense | – | –8 | – | –17 | |
| Financial result | –42 | –62 | –141 | –153 | |
| Income before income taxes, continuing operations | 407 | 330 | 1,258 | 894 | |
| Income taxes | –76 | –101 | –319 | –278 | |
| Income after taxes, continuing operations | 331 | 229 | 939 | 616 | |
| Income after taxes, discontinued operations | 3 | 2 | 4 | 4 | |
| Income after taxes | 334 | 231 | 943 | 620 | |
| thereof attributable to | |||||
| Non-controlling interests | 5 | 4 | 15 | 14 | |
| Shareholders of Evonik Industries AG (net income) | 329 | 227 | 928 | 606 | |
| Earnings per share in € (basic and diluted) | 0.71 | 0.49 | 1.99 | 1.30 |
Prior-year figures restated.
| in € million | Sep. 30, 2018 | Dec. 31, 2017 |
|---|---|---|
| Intangible assets | 6,120 | 6,105 |
| Property, plant and equipment | 6,575 | 6,495 |
| Investments recognized at equity | 47 | 47 |
| Financial assets | 229 | 327 |
| Deferred taxes | 1,240 | 1,226 |
| Other income tax assets | 13 | 14 |
| Other assets | 430 | 296 |
| Non-current assets | 14,654 | 14,510 |
| Inventories | 2,309 | 2,038 |
| Other income tax assets | 115 | 154 |
| Trade accounts receivable | 1,864 | 1,755 |
| Financial assets | 166 | 166 |
| Other assets | 320 | 313 |
| Cash and cash equivalents | 717 | 1,004 |
| 5,491 | 5,430 | |
| Assets held for sale | 74 | – |
| Current assets | 5,565 | 5,430 |
| Total assets | 20,219 | 19,940 |
| Issued capital | 466 | 466 |
| Capital reserve | 1,167 | 1,167 |
| Accumulated income | 6,401 | 6,012 |
| Treasury shares | – | – |
| Accumulated other comprehensive income | –236 | –214 |
| Equity attributable to shareholders of Evonik Industries AG | 7,798 | 7,431 |
| Equity attributable to non-controlling interests | 88 | 88 |
| Equity | 7,886 | 7,519 |
| Provisions for pensions and other post-employment benefits | 3,864 | 3,817 |
| Other provisions | 785 | 788 |
| Deferred taxes | 527 | 541 |
| Other income tax liabilities | 225 | 225 |
| Financial liabilities | 3,697 | 3,706 |
| Other payables | 46 | 57 |
| Non-current liabilities | 9,144 | 9,134 |
| Other provisions | 860 | 968 |
| Other income tax liabilities | 108 | 50 |
| Financial liabilities | 375 | 438 |
| Trade accounts payable | 1,392 | 1,449 |
| Other payables | 439 | 382 |
| 3,174 | 3,287 | |
| Liabilities associated with assets held for sale | 15 | – |
| Current liabilities | 3,189 | 3,287 |
| Total equity and liabilities | 20,219 | 19,940 |
Prior-year figures restated.
| 3rd quarter | 1st nine months | |||
|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 |
| Income before financial result and income taxes, continuing operations | 449 | 392 | 1,399 | 1,047 |
| Depreciation, amortization, impairment losses/reversal of impairment losses on non-current assets |
219 | 213 | 646 | 626 |
| Result from investments recognized at equity | –1 | –2 | –5 | –7 |
| Gains/losses on the disposal of non-current assets | –1 | –3 | –1 | –2 |
| Change in inventories | –114 | –9 | –296 | –30 |
| Change in trade accounts receivable | 61 | 89 | –122 | –79 |
| Change in trade accounts payable | –7 | 51 | –29 | 28 |
| Change in provisions for pensions and other post-employment benefits | –58 | –59 | –164 | –155 |
| Change in other provisions | 78 | 82 | –97 | –92 |
| Change in miscellaneous assets/liabilities | 35 | 69 | 73 | 34 |
| Cash outflows for interest | –21 | –25 | –82 | –86 |
| Cash inflows from interest | 5 | 7 | 17 | 35 |
| Cash inflows from dividends | – | – | 7 | 5 |
| Cash inflows/outflows for income taxes | –103 | –78 | –200 | –291 |
| Cash flow from operating activities | 542 | 727 | 1,146 | 1,033 |
| Cash outflows for investments in intangible assets, property, plant and equipment | –240 | –242 | –704 | –683 |
| Cash outflows for investments in subsidiaries | –7 | –536 | –13 | –4,116 |
| Cash outflows for investments in other shareholdings | –2 | –5 | –13 | –7 |
| Cash inflows from divestments of intangible assets, property, plant and equipment | 4 | 6 | 11 | 10 |
| Cash inflows/outflows from divestment of shareholdings | – | 2 | –1 | –10 |
| Cash inflows/outflows relating to securities, deposits and loans | –13 | –10 | –34 | 10 |
| Transfers to the pension trust fund (CTA) | – | – | –25 | –23 |
| Cash flow from investing activities | –258 | –785 | –779 | –4,819 |
| Cash outflows for dividends to shareholders of Evonik Industries AG | – | – | –536 | –536 |
| Cash outflows for dividends to non-controlling interests | –2 | –2 | –13 | –13 |
| Cash outflows for the purchase of treasury shares | – | – | –17 | –19 |
| Cash inflows from the sale of treasury shares | – | – | 17 | 20 |
| Cash inflows from the addition of financial liabilities | 2 | 447 | 89 | 643 |
| Cash outflows for repayment of financial liabilities | –111 | –74 | –195 | –159 |
| Cash inflows/outflows in connection with financial transactions | 3 | –1 | 5 | 64 |
| Cash flow from financing activities | –108 | 370 | –650 | – |
| Change in cash and cash equivalents | 176 | 312 | –283 | –3,786 |
| Cash and cash equivalents as of July 1/January 1 | 543 | 517 | 1,004 | 4,623 |
| Change in cash and cash equivalents | 176 | 312 | –283 | –3,786 |
| Changes in exchange rates and other changes in cash and cash equivalents | –2 | –6 | –4 | –14 |
| Cash and cash equivalents as on the balance sheet as of September 30 | 717 | 823 | 717 | 823 |
Prior-year figures restated.
| Nutrition & Care | Resource Efficiency | Performance Materials | ||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | 2018 | |
| External sales | 1,167 | 1,110 | 1,426 | 1,358 | 1,034 | |
| Internal sales | 7 | 7 | 13 | 8 | 44 | |
| Total sales | 1,174 | 1,117 | 1,439 | 1,366 | 1,078 | |
| Adjusted EBITDA | 212 | 188 | 338 | 311 | 172 | |
| Adjusted EBITDA margin in % | 18.2 | 16.9 | 23.7 | 22.9 | 16.6 | |
| Adjusted EBIT | 141 | 116 | 264 | 242 | 138 | |
| Capital expenditures a | 94 | 91 | 60 | 79 | 27 | |
| Financial investments | – | – | – | 547 | – |
Prior-year figures restated.
a Intangible assets, property, plant and equipment.
| Western Europe | Eastern Europe | North America | ||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 |
| External salesa | 1,623 | 1,538 | 223 | 215 | 874 | 822 |
| Capital expenditures | 104 | 120 | 3 | 1 | 43 | 50 |
Prior-year figures restated.
a External sales Western Europe: thereof Germany €659 million (Q3 2017: €647 million).
| Services | Other operations | Corporate, consolidation |
Total Group (continuing operations) |
|||||
|---|---|---|---|---|---|---|---|---|
| 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | |
| 164 | 172 | 3 | 3 | – | – | 3,794 | 3,556 | |
| 562 | 516 | 7 | 4 | –633 | –573 | – | – | |
| 726 | 688 | 10 | 7 | –633 | –573 | 3,794 | 3,556 | |
| 49 | 49 | –21 | –23 | –58 | –57 | 692 | 640 | |
| 29.9 | 28.5 | – | – | – | – | 18.2 | 18.0 | |
| 10 | 18 | –25 | –27 | –60 | –59 | 468 | 423 | |
| 33 | 27 | –5 | 3 | 1 | 1 | 210 | 236 | |
| – | 1 | 1 | – | 2 | 2 | 3 | 550 |
| Central and South America |
Asia-Pacific North | Asia-Pacific South | Middle East & Africa | Total Group (continuing operations) |
|||||
|---|---|---|---|---|---|---|---|---|---|
| 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 |
| 155 | 134 | 577 | 521 | 246 | 225 | 96 | 101 | 3,794 | 3,556 |
| 1 | 2 | 8 | 18 | 51 | 45 | – | – | 210 | 236 |
| Nutrition & Care | Resource Efficiency | Performance Materials | ||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 |
| External sales | 3,474 | 3,393 | 4,305 | 4,085 | 3,054 | 2,781 |
| Internal sales | 25 | 22 | 36 | 33 | 126 | 143 |
| Total sales | 3,499 | 3,415 | 4,341 | 4,118 | 3,180 | 2,924 |
| Adjusted EBITDA | 643 | 575 | 1,029 | 926 | 546 | 497 |
| Adjusted EBITDA margin in % | 18.5 | 16.9 | 23.9 | 22.7 | 17.9 | 17.9 |
| Adjusted EBIT | 438 | 374 | 805 | 720 | 445 | 386 |
| Capital expenditures a | 341 | 246 | 174 | 214 | 75 | 103 |
| Financial investments | 6 | 1,801 | – | 2,338 | – | 3 |
| No. of employees as of September 30 | 8,237 | 8,330 | 10,318 | 10,284 | 4,264 | 4,458 |
Prior-year figures restated.
a Intangible assets, property, plant and equipment.
| Western Europe | Eastern Europe | North America | ||||
|---|---|---|---|---|---|---|
| in € million | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 |
| External salesa | 4,907 | 4,685 | 712 | 622 | 2,527 | 2,521 |
| Goodwill as of September 30b | 2,416 | 2,380 | 54 | 54 | 1,908 | 1,904 |
| Other intangible assets, property, plant and equipment as of September 30b |
4,152 | 4,042 | 25 | 44 | 1,903 | 1,842 |
| Capital expendituresc | 277 | 348 | 4 | 3 | 131 | 150 |
| No. of employees as of September 30 | 24,470 | 24,476 | 577 | 640 | 4,899 | 5,006 |
Prior-year figures restated.
a External sales Western Europe: thereof Germany €2,017 million (9M 2017: €1,964 million).
b Non-current assets according to IFRS 8.33 b.
c Intangible assets, property, plant and equipment.
| Total Group (continuing operations) |
Corporate, consolidation |
Other operations | Services | ||||
|---|---|---|---|---|---|---|---|
| 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | |
| 11,343 10,810 |
– | – | 12 | 11 | 539 | 499 | |
| – | –1,754 | –1,869 | 18 | 19 | 1,538 | 1,663 | |
| 11,343 10,810 |
–1,754 | –1,869 | 30 | 30 | 2,077 | 2,162 | |
| 2,114 1,874 |
–183 | –168 | –71 | –69 | 130 | 133 | |
| 18.6 | – | – | – | – | 24.1 | 26.7 | |
| 1,462 1,245 |
–191 | –177 | –81 | –80 | 37 | 31 | |
| 678 | 3 | 1 | 9 | 8 | 82 | 79 | |
| 14 4,147 |
3 | 7 | – | – | 2 | 1 | |
| 36,316 36,573 |
365 | 288 | 261 | 230 | 12,875 | 12,979 |
| North America | Central and South America |
Asia-Pacific North | Asia-Pacific South | Middle East & Africa | Total Group (continuing operations) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2018 2017 |
2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 | 2018 | 2017 |
| 2,527 2,521 |
453 | 397 | 1,716 | 1,586 | 704 | 684 | 324 | 315 | 11,343 | 10,810 |
| 1,904 | 31 | 30 | 195 | 183 | 96 | 87 | 19 | 18 | 4,719 | 4,656 |
| 142 | 190 | 713 | 856 | 1,034 | 789 | 7 | 8 | 7,976 | 7,771 | |
| 150 | 4 | 6 | 24 | 42 | 238 | 107 | – | 1 | 678 | 657 |
| 5,006 | 684 | 679 | 3,686 | 3,824 | 1,819 | 1,753 | 181 | 195 | 36,316 | 36,573 |
The accounting policies applied in this quarterly statement are the same as those applied in the consolidated financial statements as of December 31, 2017, with the exception of the following changes.
Evonik applied IFRS 15 Revenue from Contracts with Customers for the first time retrospectively as of January 1, 2018. The following tables show the impact of retrospective application on the prior-year figures for the income statement and balance sheet.
| Impact of change | ||||||
|---|---|---|---|---|---|---|
| in € million | 3rd quarter 2017 | 1st nine months 2017 | ||||
| Sales | – | –42 | ||||
| Cost of sales | 1 | 30 | ||||
| Gross profit on sales | 1 | –12 | ||||
| Other operating income | – | –1 | ||||
| Other operating expense | –1 | 1 | ||||
| Income before financial result and income taxes, continuing operations | – | –12 | ||||
| Financial result | – | –1 | ||||
| Income before income taxes, continuing operations | – | –13 | ||||
| Income taxes | – | 5 | ||||
| Income after taxes | – | –8 | ||||
| thereof attributable to | ||||||
| Non-controlling interests | – | – | ||||
| Shareholders of Evonik Industries AG (net income) | – | –8 | ||||
| Earnings per share in € (basic and diluted) | – | –0.02 |
Retrospective application of this standard resulted in an increase of €1 million in both adjusted EBITDA and adjusted EBIT in the third quarter of 2017, and decreased both adjusted EBITDA and adjusted EBIT by €12 million in the first nine months of 2017. As a result of positive effects in the fourth quarter, the reduction in adjusted EBITDA was €3 million for fiscal 2017 as a whole. As a result of rounding, adjusted EBIT decreased by €4 million.
| in € million | Dec. 31, 2017 Before application of IFRS 15 |
Reclassification | Change in timing of recognition |
Change in revenue over total period |
Taxes | Dec. 31, 2017 After application of IFRS 15 |
|---|---|---|---|---|---|---|
| Deferred taxes | 1,223 | – | – | – | 3 | 1,226 |
| Other assets | 296 | – | – | – | – | 296 |
| Non-current assets | 14,507 | – | – | – | 3 | 14,510 |
| Inventories | 2,025 | – | 14 | –1 | – | 2,038 |
| Trade accounts receivable | 1,776 | – | –21 | – | – | 1,755 |
| Financial assets | 159 | – | – | 7 | – | 166 |
| Other assets | 314 | – | – | –1 | – | 313 |
| Current assets | 5,432 | – | –7 | 5 | – | 5,430 |
| Total assets | 19,939 | – | –7 | 5 | 3 | 19,940 |
| Equity | 7,527 | – | –8 | –3 | 3 | 7,519 |
| Other payables | 57 | – | – | – | – | 57 |
| Non-current liabilities | 9,134 | – | – | – | – | 9,134 |
| Other provisions | 1,035 | –67 | – | – | – | 968 |
| Financial liabilities | 371 | 67 | – | – | – | 438 |
| Other payables | 373 | – | 1 | 8 | – | 382 |
| Current liabilities | 3,278 | – | 1 | 8 | – | 3,287 |
| Total equity and liabilities | 19,939 | – | –7 | 5 | 3 | 19,940 |
Under IFRS 15, the rebate and bonus agreements previously recognized as other provisions are included in financial liabilities
as refund liabilities. As of December 31, 2017, this resulted in reclassifications totaling €67 million.
Evonik has applied the new accounting standard IFRS 9 Financial Instruments for the first time for the fiscal year starting on January 1, 2018. In accordance with the transitional provisions of IFRS 9, the comparative data have not been restated, with the exception of certain aspects of hedge accounting. Retrospective application is mandatory where the intrinsic value of an option is designated as the hedging instrument in a hedging relationship. Here, IFRS 9 specifies that changes in the fair value of the time value of the options over the term of the hedging relationship must initially be recognized in other comprehensive income and subsequently released through a basis adjustment or directly to profit or loss, depending on the type of hedged transaction. As of the transition date, Evonik did not have any such cases.
However, in 2017 the Group recognized options transactions that expired in September 2017. Their purpose was to hedge the purchase price of the silica business of J.M. Huber Corporation, Atlanta (Georgia, USA). The change in fair value recognized in profit or loss in the third quarter of 2017 was €9 million. The countereffects in the second and third quarters of 2017 canceled each other out in the third quarter of 2017.
| Impact of change | |||||||
|---|---|---|---|---|---|---|---|
| in € million | 3rd quarter 2017 | 1st nine months 2017 | |||||
| Financial result | 9 | – | |||||
| Income before income taxes, continuing operations | 9 | – | |||||
| Income taxes | –3 | – | |||||
| Income after taxes | 6 | – | |||||
| thereof attributable to | |||||||
| Non-controlling interests | –1 | – | |||||
| Shareholders of Evonik Industries AG (net income) | 7 | – | |||||
| Earnings per share in € (basic and diluted) | 0.02 | – |
Retrospective application did not alter the adjusted financial result and adjusted net income reported for the third quarter of 2017 and the first nine months of 2017.
The role of the Corporate Innovation unit is to manage and direct innovations. Since January 1, 2018, the costs incurred for this unit have been included in research and development expenses instead of in general administrative expenses as in the past. This results in an adjustment of €4 million for the third quarter of 2017 and of €13 million for the first nine months of 2017. The effect for 2017 as a whole is €18 million.
| Event | Date |
|---|---|
| Report on Q4 2018 and FY 2018 | March 5, 2019 |
| Interim report Q1 2019 | May 7, 2019 |
| Annual Shareholders' Meeting 2019 | May 28, 2019 |
| Interim report Q2 2019 | August 1, 2019 |
| Interim report Q3 2019 | November 5, 2019 |
Evonik Industries AG Rellinghauser Strasse 1–11 45128 Essen, Germany www.evonik.com
Communications Phone +49 201 177-3315 [email protected]
Phone +49 201 177-3146 [email protected]
BISSINGER[+] GmbH
The English version is a translation of the German version and is provided for information only.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.